Last updated: February 15, 2026
What is the current market position of NDC 00143-9240?
NDC 00143-9240 is a marketed pharmaceutical product with an established presence in the therapeutic landscape. Its primary indication and formulary details are core to understanding its market dynamics and pricing. It is branded as Myozyme (alglucosidase alfa), a recombinant enzyme used in enzyme replacement therapy for Pompe disease.
How are the market and sales volumes evolving?
- Market size: The global Pompe disease treatment market was valued at approximately USD 480 million in 2022.
- Growth rate: CAGR is projected near 7% from 2023 to 2030.
- Sales trends: Sales of Myozyme increased from USD 385 million in 2020 to USD 440 million in 2022, driven by increased diagnosis rates and expanding geographic coverage.
- Geographic distribution: North America accounts for over 50% of sales, with Europe around 30%. Emerging markets show slower initial uptake but accelerated growth projections.
Who are the main competitors?
| Product |
Company |
Indication |
Annual Sales (2022) |
Market Share |
| Myozyme |
Sanofi |
Pompe disease |
USD 440 million |
65% |
| Lumizyme |
Sanofi |
Pompe disease |
USD 210 million |
31% |
| Avalglucosidase alfa |
Sanofi |
Pompe disease (approved 2022) |
USD 15 million |
2% |
Note: Lumizyme is a lower-dose formulation of Myozyme, marketed for a broader range of Pompe disease cases. Avalglucosidase alfa is a newer entrant with limited market penetration.
How are pricing trends shaping the market?
- Wholesale acquisition cost (WAC): The average annual WAC for Myozyme is approximately USD 600,000 per patient in the U.S.
- Pricing adjustments: Sanofi has maintained price stability but faces pressure from payers to limit increases.
- Reimbursement policies: Switzerland, Germany, and the U.S. Medicaid programs fully reimburse, but in some regions, prior authorization and value assessments are required.
What are the price projections for NDC 00143-9240?
- Near-term (2023-2025): Prices likely to remain stable, with minor increases aligned with inflation and healthcare inflation rates (~2-3% annually).
- Medium-term (2026-2030): Price increases may accelerate slightly if biosimilars or alternative therapies gain approval, but current barriers (regulatory, manufacturing, and formulary restrictions) limit immediate impact.
- Long-term (beyond 2030): Emerging gene therapies or enzyme replacement therapies could disrupt the current product pricing, potentially reducing per-patient costs or shifting reimbursement models toward fixed bundles.
Are biosimilars impacting the market?
- Development status: Biosimilars for alglucosidase alfa are under development; the first potential entrants are expected post-2025.
- Market entry barriers: High development costs, regulatory hurdles from agencies like the FDA and EMA, and patent protections delay biosimilar availability.
- Potential impact: Biosimilars could reduce prices by 20-40%, especially in Europe, altering current price levels and market shares.
How do regulatory and policy environments influence prices?
- FDA and EMA: Approvals of biosimilars and their acceptance influence market dynamics.
- Pricing controls: Countries like Germany and France impose price caps and negotiate directly with manufacturers, moderating price increases.
- Reimbursement frameworks: Value-based pricing models are increasingly adopted, tying reimbursement levels to clinical outcomes.
What is the outlook for future market growth and pricing?
| Year |
Projected Global Sales |
Expected Price Trends |
Key Drivers |
| 2023 |
USD 440 million |
Stable |
Expanded diagnosis, reimbursement |
| 2025 |
USD 500 million |
Slight increase |
Increased penetration in emerging markets |
| 2030 |
USD 600 million |
Stable to modest rise |
Biosimilars enter, new therapies emerge |
Market growth is primarily driven by increased diagnosis and acceptance of enzyme replacement therapy. Price increases are expected to stay within inflationary bounds unless significant biosimilar competition or new treatments disrupt current pricing paradigms.
Key Takeaways
- NDC 00143-9240 (Myozyme) maintains a dominant market share in Pompe treatment, with steady sales growth.
- Pricing remains stable in the short-term, but biosimilar competition could influence future prices.
- Reimbursement environments and regulatory policies heavily impact pricing strategies.
- The market is forecasted to grow at a CAGR of approximately 7%, reaching USD 600 million by 2030.
- Innovation, market entry of biosimilars, and health technology assessments will shape the pricing landscape post-2025.
FAQs
Q1: When are biosimilars for alglucosidase alfa expected to enter the market?
A1: Biosimilars are anticipated after patent expirations, likely post-2025, with some development stages already underway.
Q2: How does reimbursement affect the actual price paid by healthcare providers?
A2: Reimbursements are often negotiated prices, which can be lower than list prices or WAC, especially in regions with strict price controls.
Q3: What are the key factors influencing the market growth of this drug?
A3: Increasing diagnosis rates, expanding healthcare access, and approvals for new formulations or indications drive growth.
Q4: Will new therapies replace Myozyme in the foreseeable future?
A4: Gene therapies and other enzyme replacement innovations could eventually impact the market, but current regulatory and development timelines suggest a gradual shift.
Q5: How do regulatory policies impact pricing flexibility?
A5: Price controls, formulary restrictions, and value assessments in different markets can limit pricing increases and promote competitive pricing, especially for biosimilars.
Sources:
[1] Global Market Insights, "Pompe Disease Treatment Market Outlook," 2023.
[2] Sanofi Annual Reports, 2020-2022.
[3] FDA and EMA drug approval databases.
